Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: May 13, 2025
Cancer
is
a
complex
and
heterogeneous
disease
that
often
requires
multifaceted
treatment
strategies
to
achieve
optimal
therapeutic
outcomes.
Given
the
limitations
of
single-agent
therapies,
particularly
in
face
intricate
biological
signaling
networks
resistance,
there
growing
need
for
combinatory
approaches.
This
article
presents
novel
hypothesis:
simultaneous
use
ribosome-inactivating
proteins
(RIPs)
mesenchymal
stem
cells
(MSCs)
or
MSC-derived
extracellular
vesicles
(EVs)
cancer
treatment.
RIPs,
with
their
potent
cytotoxic
properties,
can
target
tumor
effectively,
while
MSCs,
known
tumor-homing
abilities
regenerative
potential,
serve
as
delivery
vehicles,
potentially
enhancing
targeting
precision
reducing
systemic
toxicity
RIPs.
hypothesis
explores
synergistic
potential
combining
these
two
modalities,
leveraging
advantages
both
techniques
create
more
effective
strategy.
By
RIPs’
ability
inhibit
protein
synthesis
MSCs
EVs’
capability
modulate
microenvironment
deliver
agents.
approach
offers
promising
avenue
overcoming
cancer’s
inherent
complexity.
However,
challenges
remain,
such
optimizing
dosing
protocols,
addressing
safety
concerns,
ensuring
efficient
drug
delivery.
Future
research
clinical
trials
are
necessary
validate
this
combination
viable
therapy.
